Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of TQB3616 Capsules Plus Endocrine Therapy in HR-positive, HER2-negative Recurrent/Metastatic Breast Cancer After CDK4/6 Inhibitor Resistance
CTR20244301Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2025; status: active.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20244301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244301.